STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial

While overall survival data remain immature, the results pointed to a favourable trend.

Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz

The company highlighted continued demand strength and pricing resilience despite global disruptions

Sun's cancer drug shines delivering 50% response rate with long-lasting tumor control

These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC

Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

APHI welcomes CCI order on integrated healthcare delivery model

The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine